Clinical Trials
Scancell updates on cancer vaccine Phase I clinical trial
The Cohort Review Committee has approved Scancell to further escalate cancer vaccine SCIB1 dose to 4mg from the current 2mg in the Phase I clinical trial and recruitment of the final group of patients as planned. ...
Clinical Trials
Aeras, OETC commence TB drug Phase IIb trial
Aeras and the Oxford-Emergent Tuberculosis Consortium (OETC) have commenced a Phase IIb trial to investigate a new experimental tuberculosis vaccine in TB patients with human immunodeficiency virus (HIV) infection. The trial will evaluate the HIV patients...
Clinical Trials
Alnylam concludes liver cancer drug Phase I trial
US based drug developer Alnylam Pharmaceuticals has concluded an open label, multi-center, dose escalation Phase I trial evaluating ALN-VSP as a treatment for advanced solid tumors with liver involvement. ALN-VSP is a systemically delivered RNAi therapeutic...
Clinical Trials
Sinapis Pharma concludes Phase I stroke drug trial
Sinapis Pharma has concluded first Phase I clinical trial of oral and IV administration of methamphetamine HCl for the treatment of stroke and traumatic brain injury. The single-center, open-label, randomized, two-period, two-treatment, two-sequence, single dose, crossover...
Clinical Trials
Phase 3 Study of YERVOY Metastatic Melanoma Meets Primary Endpoint of Overall Survival
Bristol-Myers Squibb Company announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY™ (ipilimumab) prolonged the lives of patients with metastatic melanoma. The data were published today in the New England Journal of Medicine and...
Clinical Trials
Roche announces data to show Avastin based regimen halved the risk of disease getting worse in women with recurrent ovarian cancer
Roche announced results from OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer. Women who received...
Clinical Trials
Adaptimmune announces Opening of Phase I/II Clinical Trial in Multiple Myeloma
Adaptimmune announced that it has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy. ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read